HSPA1A and cancer: The recommendation for this combination therapy modality was based on the results that the level of HSP70 was upregulated by HSP90 inhibitors and that dual inhibition of HSP70 and HSP90 could simultaneously disrupt the key signaling pathways in cancers [163,165,166].